RAD001 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tuberous Sclerosis Complex

Conditions

Tuberous Sclerosis Complex

Trial Timeline

Jan 1, 2011 → Dec 1, 2014

NCT ID

NCT01289912

About RAD001 + Placebo

RAD001 + Placebo is a phase 2 stage product being developed by Novartis for Tuberous Sclerosis Complex. The current trial status is completed. This product is registered under clinical trial identifier NCT01289912. Target conditions include Tuberous Sclerosis Complex.

What happened to similar drugs?

1 of 8 similar drugs in Tuberous Sclerosis Complex were approved

Approved (1) Terminated (1) Active (6)

✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved

🔄Everolimus (RAD001) + Everolimus PlaceboNovartisPhase 3

🔄Everolimus + PlaceboNovartisPhase 3

🔄RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)NovartisPhase 3

🔄everolimusNovartisPhase 3

❌GWP42003-PJazz PharmaceuticalsPhase 3

🔄GWP42003-PJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02991807	Phase 1/2	Completed	Jun 12, 2017	Dec 22, 2021	PTEN Gene Mutation
NCT01289912	Phase 2	Completed	Jan 1, 2011	Dec 1, 2014	Tuberous Sclerosis Complex
NCT00466102	Phase 2	UNKNOWN	Dec 1, 2006	Dec 1, 2012	Breast Cancer
NCT00410124	Phase 3	Completed	Nov 1, 2006	Oct 1, 2011	Metastatic Renal Cell Carcinoma

Competing Products

13 competing products in Tuberous Sclerosis Complex

See all competitors

Product	Company	Stage	Hype Score
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	40
Everolimus + Placebo	Novartis	Phase 3	40
RAD001	Novartis	Phase 1/2	32
Placebo + Everolimus (RAD001)	Novartis	Phase 2	31
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	40
Everolimus	Novartis	Phase 1/2	32
everolimus (RAD001)	Novartis	Phase 1/2	32
everolimus	Novartis	Phase 3	44
sirolimus	Pfizer	Phase 2	31
GWP42003-P	Jazz Pharmaceuticals	Phase 3	29
GWP42003-P	Jazz Pharmaceuticals	Phase 3	37
GWP42003-P + Placebo	Jazz Pharmaceuticals	Phase 3	37
Cannabidiol Oral Solution [Epidiolex]	Jazz Pharmaceuticals	Approved	44